Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose Romiplostim N01 Monotherapy in Aplastic Anemia with PRF1 or SBDS Mutations
ChiCTR2600117237Phase 3Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jan 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of romiplostim in acquired aplastic anemia (AAA) (3 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Proportion of patients achieving hematological response at Week 8. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
romiplostim
03
Conditions
acquired aplastic anemia (AAA)
Beyond the preview
Go deeper on ChiCTR2600117237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117237.